Few clues to flotation fever in past performance
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Corporate venture firms – dedicated followers of fashion?
Eagerly pursuing all the latest fads and trends.
Biotech floats come back with a vengeance
The biotech IPO market records its first billion dollar quarter in two years as demand for new issues recovers.
